Quarterly report pursuant to Section 13 or 15(d)

Interim Consolidated Statements of Changes in Shareholders' Equity (unaudited)

v3.20.1
Interim Consolidated Statements of Changes in Shareholders' Equity (unaudited) - USD ($)
$ in Thousands
Common Stock
Additional paid in capital
Accumulated deficit
Preferred A Shares (pre-merger-BiomX Ltd.)
Preferred B Shares (pre-merger-BiomX Ltd.)
Total
Balance at Dec. 31, 2018 [1] $ 64,410 $ (21,609) $ 1 $ 1 $ 42,803
Balance, shares at Dec. 31, 2018 [2] 2,307,871     7,543,831 5,170,357  
Issuance of shares 1,800 [1] 1,800
Issuance of shares, shares [2]     308,628 [2]  
Share-based payment 304 304
Net loss (3,225) (3,225)
Balance at Mar. 31, 2019 [1] 66,514 (24,834) $ 1 $ 1 41,682
Balance, shares at Mar. 31, 2019 [2] 2,307,871     7,543,831 5,478,985  
Balance at Dec. 31, 2019 $ 2 126,626 (42,172)     84,456
Balance, shares at Dec. 31, 2019 22,862,835          
Exercise of options [1] 106       $ 106
Exercise of options, shares 57,325         57,325
Share-based payment 337     $ 337
Net loss     (5,901)     (5,901)
Balance at Mar. 31, 2020 $ 2 $ 127,069 $ (48,073)     $ 78,998
Balance, shares at Mar. 31, 2020 22,920,160          
[1] Less than $1 thousand.
[2] Number of shares has been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the reverse recapitalization transaction consummated on October 28, 2019 (refer to Note 1).